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Abstract: Esophageal cancer (EC) is an aggressive disease with a poor prognosis. Treatment
resistance is a major challenge in successful anti-cancer therapy. Pathological complete response after
neoadjuvant chemoradiation (nCRT) is low, thus requiring therapy optimization. The Hedgehog
(HH) pathway has been implicated in therapy resistance, as well as in cancer stemness. This article
focusses on the HH pathway as a putative target in the treatment of EC. Immunohistochemistry on
HH members was applied to EC patient material followed by modulation of 3D-EC cell cultures,
fluorescence-activated cell sorting (FACS), and gene expression analysis after HH pathway modulation.
Sonic Hedgehog (SHH) and its receptor Patched1 (PTCH1) were significantly enriched in EC resection
material of patients with microresidual disease (mRD) after receiving nCRT, compared to the control
group. Stimulation with SHH resulted in an up-regulation of cancer stemness in EC sphere cultures,
as indicated by increased sphere formation after sorting for CD44+/CD24− EC cancer stem-like cell
(CSC) population. On the contrary, inhibiting this pathway with vismodegib led to a decrease in
cancer stemness and both radiation and carboplatin resistance. Our results strengthen the role of
the HH pathway in chemoradiotherapy resistance. These findings suggest that targeting the HH
pathway could be an attractive approach to control CSCs.
Keywords: Esophageal cancer; Hedgehog pathway; cancer stem cells; treatment resistance
1. Introduction
Despite modern advances in the treatment of esophageal cancer (EC), most patients still face a
poor prognosis primarily due to locoregional advanced disease, metastases at the time of diagnosis
and early recurrences after initial curative treatment [1]. Esophageal adenocarcinoma (EAC) arising
from gland tissue is one of the two main histological EC types and has the fastest growing incidence in
the western world, increasing 300% within the last 30 years [2]. EAC is currently the predominant
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type in the western world beyond esophageal squamous cell carcinoma (ESCC), which arises from the
epithelium [2,3]. If resectable, both types are commonly treated with neoadjuvant chemoradiotherapy
(nCRT) followed by surgery. However, only 29% of these tumors will reach a pathologic complete
response (pCR), while >50% respond partially and around 20% will not respond at all to nCRT [4].
Moreover, most patients will relapse within 2.5 years [5]. These numbers indicate that there is an
urgent need for treatment optimization. Elucidating tumor regulatory mechanisms that are on the
basis of sustained disease might provide new therapeutic targets. Furthermore, it may provide
tools for developing novel ways to predict therapy response preventing patients from undergoing
unnecessary therapy.
The Hedgehog (HH) pathway, which plays a major key role in embryogenesis, is essential for
tissue development and differentiation [6,7]. In adult tissue, the HH pathway is inactive in normal
tissues except for stem and progenitor cells where it plays a role in the maintenance of homeostasis
and tissue repair [6,7]. Three mammalian HH ligands have been described, namely Sonic Hedgehog
(SHH), Desert Hedgehog (DHH) and Indian Hedgehog (IHH). Of these three ligands, SHH is by
far the best characterized [6,7]. In the presence of SHH ligand, SHH binds to the Patched1 (PTCH1)
transmembrane receptor relieving the inhibitory effect on Smoothened (SMO). Consequently, a cascade
of reactions leads to the activation of GLI family zinc finger 1,2 and 3 transcription factors (GLI1, GLI2
and GLI3). Upon binding of the GLI transcription factors to a protein complex including Suppressor of
Fused (SUFU) (an essential component of HH signaling in vertebrates [8]), GLI transcription factors
translocate to the nucleus where they control the transcription of target genes [7,9,10]. PTCH1 is
transcriptionally induced upon activation of SMO along with the other pathway targets. Target genes,
such as PTCH1 and GLI1, play a role in maintaining the regulation of the pathway itself, while others
promote cell survival. Aberrant activation or mutation in the key members of the HH pathway is
associated with the development of cancer and resistance to conventional anticancer therapy [7,9].
Moreover, the HH pathway has been linked to a population of cells called cancer stem-like cells
(CSCs) which is a major contributor of therapy resistance [11–13], while PTCH1 is often associated
with cancer stemness [14]. It has previously been shown that CSCs possess features of normal stem
cells such as the ability to self-renew and to generate all other cells of the tumor [11–13], and may
play an important role in tumor-initiation, metastases, recurrences and therapy resistance in different
kinds of cancers [15]. Therefore, this population of cells is known for its aggressiveness and should be
eradicated. Previously, Smit et. al. [16] showed that a subpopulation of a commonly used CSC marker
CD44 expressing cells the CD44+/CD24− expressing cells, displayed more potently CSC characteristics.
In vitro, CD44+/CD24− cells yield significantly more spheres and are more resistant to irradiation.
In vivo, this population forms tumors earlier which also grow larger in size. Serial transplantation
experiments of first, second and third generation tumors demonstrated a strong correlation between
the proportion of CD44+/CD24− cells and the in vivo growth rate [16]. Furthermore, CD44+/CD24−
was found to be present in 50% of pretreatment tumor biopsies of patients with residual EAC after
treatment in surgical specimens but absent in all biopsies of patients who had a pathological complete
response after nCRT [16]. These results suggest that CSCs are more enriched in the CD44+/CD24−
population compared to CD44+/CD24+ and the unsorted population, and could be used as a readout
for esophageal CSCs. Interestingly, the combination CD44+/CD24− is also commonly used to isolate
breast CSCs [17].
Thus, studying the HH pathway in EC may reveal a new way to eradicate CSCs leading to reduced
therapy resistant tumors. Our aim is to explore whether the HH pathway can be considered as a
potential target for future anti-CSC EC therapy.
2. Results
To investigate if the HH pathway is involved in regulating EC CSCs, the level of expression of the
HH members PTCH1 and SHH were assessed in EC resection material from patients that underwent
a surgical resection in our center during the period 2006 and 2011. Sixteen tumor tissue specimens
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from non or marginally responding EC patients to nCRT (microresidual disease, mRD group with
Mandard tumor regression grade 4 and 5) were compared to 32 matched control tumor specimens of
patients who only had undergone radical surgery (S group). The latter group with unknown therapy
responsiveness represents a mix of all potentially responding groups. Indeed, both PTCH1 and SHH
were significantly higher expressed in mRD tissue compared to S tissue (both p = 0.04, Figure 1A,B).
These results indicate that the HH pathway may be related to therapy resistance.
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To validate the impact of the HH pathway in the regulation of CSCs that might play a fundamental
role in the observed therapy resistance in patient derived tumor resection material, CD44+/CD24−
was taken as a read-out for cancer stemness after first verifying the sphere forming ability, as a
hallmark of CSCs, of this population in vitro. The sphere forming potential of two subpopulations
of cells were isolated by sorting the 3–15% of the outer extreme of CD44+/CD24− CSC population
and CD44+/CD24+ non-CSC population, in OE21 and OE33 EC cell lines isolated at 70% confluency
(Figure 2A). Five percent of the outer extreme of each subpopulation were isolated by FACS. Indeed,
as shown previously [16], the CD44+/CD24− population formed significantly more spheres when
compared to CD44+/CD24+ population in both OE21 and OE33 cell lines (p = 0.01 and p = 0.02
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Next, in order to identify a pathway in an unbiased way that may be involved in the regulation of
the CD44+/CD24−CSC population, a qPCR array of 84 genes related to cancer stemness was performed
on the subpopulations of both OE21 and OE33 cells and were compared to previously harvested OE21-
and OE33-derived xenograft tumor controls representing a more differentiated population [16]. In
this way, genes that were up-regulated in CD44+/CD24− expression compared to the control could be
identified (Supplementary Table S1 and Figure 3A). Genes that had >2-fold upregulation compared
to controls were considered to be upregulated. In OE21, multiple genes were >2-fold upregulated
including PTCH1, a member of the HH pathway. In OE33, fewer genes displayed >2-fold upregulation,
among which was found to be again PTCH1 (Supplementary Table S1 and Figure 3B). To narrow
down genes, the differences of expression between the CD44+/CD24− population and CD44+/CD24+
population were compared to their controls. Interestingly, PTCH1 was upregulated in CD44+/CD24−
and CD44+/CD24+ populations in both cell lines compared to their controls (OE21 9.31 and 3.67, and
OE33 2.37 and 1.71 respectively). These findings were validated by separate qPCR analyses (both cell
lines p = 0.04, Figure 3C).
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Figure 3. PTCH1 is up-regulated in CD44+/CD24− CSC population in both OE21 and OE33 cell lines
according to a qPCR array of 84 genes related to cancer stemness. (A) Relative mRNA expression of
CSC related genes in OE21 CD44+/CD24− CSC population, CD44+/CD24+ population and control
(obtained from more differentiation form the cell lines derived xenograft tumors, [16]). Shown genes
express >2 fold in CD44+/CD24− population compared to control. Control is set on 1. (B) Relative
mRNA expression of CSC related genes in OE33 CD44+/CD24− CSC population, CD24+/CD44+
population and control. Shown genes express >2 fold in CD44+/CD24− population compared to
control. (C) Validation of relative mRNA expression of PTCH1 in CD44+/CD24− CSC population,
CD24+/CD44+ population and control in OE21 and OE33 by qPCR. PTCH1 was 3.8 fold up-regulated
in CD44+/CD24− CSC population compared to control in OE21 (p = 0.04, N = 3) and 2.3 fold in OE33
(p = 0.04, N = 5). Error bars represent standard deviation.
To assess the role of the HH pathway in CSC regulation, the HH pathway was modulated by
exogenously adding its ligand SHH (0.4 µg/mL) to CD44+/CD24− and CD44+/CD24+ cells after sorting
(similar gating strategies as shown in Figure 1A were used, Supplementary Figure S1A) in both OE21 and
OE33. After adding, SHH induced a significant increase in sphere forming potential in both CD44+/CD24−
and CD44+/CD24+ sorted cells when compared to control in OE21 and OE33 (Figure 4A), whereas the
solvent (PBS + 0.1% BSA) did not affect the sphere forming ability of either cell line (data not shown). In
contrast, inhibition of the HH pathway using vismodegib (5 nM; a concentration chosen based on the
viability of cells treated with vismodegib alone (Supplementary Figure S2)) resulted in a reduction of the
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CD44+/CD24− CSC phenotype in OE21 and OE33 cells when compared to controls (Figure 4B, FACS
gating strategies are shown in supplementary Figure S1B). Moreover, sphere forming ability also decreased
after vismodegib treatment in both OE21 and OE33 cells (Figure 4C). Compared to other cells within a
tumor, it has previously been shown that CSCs are more resistant to many forms of cancer treatments [15].
Therefore, modulation of the CSC population should illicit a change in radioresistance in OE-21 cells [16].
To this end, OE-21 cells were photon irradiated or treated with carboplatin (a common chemotherapeutic
drug used for esophageal cancer treatment) following 48 hours treatment with vismodegib and their
clonogenic capability was assessed. Indeed, vismodegib-treated cells were found to be more sensitive to
both radiation and carboplatin treatment than control cells (Figure 4D,E). These findings indicate that the
HH pathway may be involved in the regulation of the CD44+/CD24− CSC population increasing cancer
stemness and as a consequence may result in an increased therapy resistance. Inhibiting the pathway
with vismodegib may be of therapeutic value and should be explored further.
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inhibitor, deselects for the CD44+/CD24− population, decreases sphere formation and increases
radiosensitivity. (A) Relative number of spheres formed in OE21 and OE33 after sorting for
CD44+/CD24− and CD44+/CD24+ populations with the controls set on 1. Cells treated with SHH
formed significantly more spheres in CD44+/CD24− and CD44+/CD24+ populations compared to their
controls (DMSO-treated) (OE21: 1.97 (p = 0.009, N = 3) and 2.33 (p = 0.03, N = 3) fold respectively.
OE33: 1.68 (p = 0.04, N = 3) and 2.18 (p = 0.04, N = 3) fold respectively. Spheres were counted after five
days. (B) Percentage of CD44+/CD24− expression in OE21 and OE33 (unsorted populations) control
(DMSO-treated) and vismodegib (5 nM) treated cells. Vismodegib treated cells showed significantly a
deselection of the CD44+/CD24− phenotype in both cell lines compared to (DMSO-treated) controls
(OE21 p = 0.02, OE33 p = 0.04, N = 4). (C) Amount of spheres formed in OE21 and OE33 control
and vismodegib (5 nM) treated cells. Spheres were significantly lower in vismodegib treated cells
compared to control (DMSO-treated) in OE21 (p = 0.008, N = 3) and OE33 (p = 0.03, N = 4). Survival
of vismodegib-treated cells in response to (D) radiation and (E) Carboplatin. Error bars represent
standard deviations, *p < 0.05, **p < 0.01.
3. Discussion
In this study, we demonstrated that the HH pathway is up-regulated in nCRT patients with
Mandard 4 and 5 statuses after reviewing the resection material and moreover it may be a key player
in the regulation of cancer stemness as shown by the change in the amount CD44+/CD24− CSC
population upon HH pathway modulation. The first observation can be explained by the fact that
nCRT may activate the HH pathway and in turn making cells acquiring more CSC features including
the therapy resistance characteristic [18]. Another clarification for this phenomenon could be that
a subset of cancer cells already has an activated HH pathway prior to therapy that renders them to
survive chemo- and radiotherapy [19–22]. Most likely, a combination of both may occur. The S group
contains patients from <2006 when radical surgery was the standard treatment for esophageal cancer
implicating that this group includes non-responders, partial responders and complete responders. This
could be the reason why the results of PTCH1 and SHH expression between this group and the mRD
group are more condensed. Next, we verified these results in an unbiased qPCR array experiment
with sorted CD44+/CD24− OE21 and OE33 cells compared to sorted CD44+/CD24+ OE21 and OE33
cells, and dissociated OE21 and OE33 cells previously harvested from mouse xenograft tumors [16].
Cells from xenografts represent a more differentiated and heterogeneous group of cells, and thus
represent all four populations of CD44 and CD24 following FACS analysis. Therefore, the xenograft
group was considered as our control group, as the original cell lines did not show expression of the
CD44−/CD24+ or CD44−/CD24−. On the other hand, cells obtained from xenografts may be influenced
by tumor microenvironmental factors, such as hypoxia activating, a number of CSC-related pathways
including the HH pathway. However, our qPCR data show that PTCH1 expression is lower in our
control group compared to the other two groups indicating that even with the potential influence of the
tumor microenvironment, PTCH1 expression is less compared to a ‘pure’ CD44+/CD24− population
suggesting the tumor is indeed composed of more differentiated cells. Co-labelling CD44, CD24 and
PTCH1 for flow cytometry purposes was not favorable due to the lack of conjugated antibodies against
PTCH1. While vismodegib binds directly to PTCH and SMO and thereby inhibits the activation of
GLI [23], the effect of vismodegib treatment on the expression of other genes which were found to
be upregulated in the CSC subpopulation but not directly involved in the HH pathway (Figure 3)
was not investigated. It would be interesting to determine if the upregulation of these genes was also
abrogated upon vismodegib treatment, as this may indeed further confirm that the CSCs in general
have been targeted. RNA-seq analysis may reveal other interesting targets not present on our cancer
stemness dedicated array.
To date, we are the first to show the importance of the HH pathway in controlling cells in a
specific CSC population in EC. The activation of the HH pathway in subsets of EC has been shown
previously [19–22] and is in line with our study. In addition, some studies have shown the association
of the HH pathway with therapy resistance but did not address the involvement of specific CSC
Cancers 2019, 11, 821 8 of 13
populations [20,22]. We have demonstrated that inhibiting the HH pathway is related to a reduction
of cells with the cancer stem cell related phenotype (CD44+/CD24−), less sphere forming capability
and more radiosensitivity. Although vismodegib is being tested in the clinic, xenograft models in
combination with HH pathway modulation will provide more information on the potential therapeutic
effectiveness. Furthermore, it would be important for future studies to confirm if the effect was indeed
directly due to the actions of vismodegib on the HH pathway using other HH-targeting molecules
which are currently being used in clinical trials, such as LDE225 [24–26].
Vismodegib, also known as GDC-0449, is a small molecule HH inhibitor that blocks the
interaction between the PTCH-receptors and their ligands [27]. The choice of vismodegib is based
on its advantageous characteristics. It is more potent than the better known cyclopamine and
has more favorable pharmaceutical characteristics. Moreover, it has already been FDA approved
for advanced basal cell carcinoma [27]. Vismodegib is currently used in early trials for treatment
of basal cell carcinomas and medulloblastoma, showing promising early indications in enhancing
treatment responses [28–30]. Therefore, vismodegib could be a promising drug to target esophageal
CSC populations.
4. Material and Methods
4.1. Patient Material
Sixteen tumor tissue specimens of microscopic residual disease (mRD group) from EC patients
who showed little or no response to nCRT (Mandard tumor regression grade 4 and 5) following
surgical resection at the University Medical Center Groningen, during the period 2006 and 2011 were
included in the primary study group. Only patients with histologically proven ESCC or EAC after
curative resections were included. Some patient samples were excluded due to lack of sufficient
tissue. Furthermore, all patients had to be treated with nCRT according to the CROSS regimen [4,5].
These 16 tumor specimens were matched (1:2) to 32 control tumor specimens of patients who have
only undergone surgery (S group). The S group contains patients from the period before 2006 when
radical surgery alone was considered as standard therapy for EC. When extrapolating this group,
it will represent the whole treatment group of current nCRT, including none, partial and complete
responders. Matching was based on histology (EAC or ESCC) and depth of tumor invasion (T-stage).
Tissue microarrays (TMAs) were constructed as previously described [16]. The study was conducted
according to the guidelines of our Ethical Institutional board (www.ccmo.nl). Archival tissue was
handled according to the Dutch Code for proper use of Human Tissue (www.federa.org).
This study did not require an ethics approval or a consent to participate. The human material
used in this study was archival tissue. The study was conducted according to the guidelines of our
Ethical Institutional board (www.ccmo.nl). Archival tissue was handled according to the Dutch Code
for proper use of Human Tissue (www.federa.org). This study was performed in accordance with the
Declaration of Helsinki.
4.2. Immunohistochemical Staining and Evaluation
Immunohistochemical staining was performed on 5µm tissue sections from archival material using
primary antibodies against PTCH1 (Anti-Patched/PTCH1 antibody Abcam 53715 1:100), SHH (anti
SHH 1:100 Abcam 53281) (Abcam, Cambridge, MA, USA), CD44 (anti-mouse/human CD44 Antibody
Biolegend Cat.103002 1:100) (Biolegend, London, United Kingdom) and CD24 (anti CD24 Abcam
31622 1:100). The tissue sections were de-paraffinized and subsequently immersed in PBS 2% hydrogen
peroxidase to block endogenous peroxidase activity. Antigen-retrieval was performed and the sections
were incubated overnight at 4 ◦C with the primary antibodies. Tissue sections were then incubated
with biotinylated secondary antibodies at 1:300 dilutions. The ABC complex was formed using the
Vectastain Elite ABC HRP kit (Vector Laboratories, Peterborough, United Kingdom). This complex
was visualized with SIGMA FAST 3,3′-diaminobenzidine tablets (Merck KGaA, Darmstadt, Germany).
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In the final step, sections were counterstained with haematoxylin. Immunohistochemical staining was
digitized using Aperio (ASSA ABLOY, Raamsdonksveer, The Netherlands) or Hamamatsu (Almere,
The Netherlands). These systems are able to process immunohistochemical slides with high quality,
speed and reliability for whole slide imaging. These slides were scored by two independent blinded
researchers (D.W. and J.K.S.) using the IRS method without prior knowledge of the clinical outcome.
Random samples of each marker were validated by the pathologist A.K. The percentage of positive
cells was scored into four categories: (0) no staining, (1) <10%, (2) 10–50%, (3) 51–80% and (4) 81–100%.
Intensity was scored as (0) negative, (1) weak, (2) medium and (3) strong. An Immuno-Reactivity Score
(IRS) was calculated by multiplying the percentage of positive cells with the intensity score resulting in
a score on a scale of 0–12. For evaluation of SHH the IRS was divided into four groups: negative (IRS
0–1, immunoscore 0); weak positive staining (IRS 2–3, immunoscore 1); moderate positive staining
(IRS 4–8, immunoscore 2) and strong positive staining (IRS 9–12, immunoscore 3) [31]. Since almost all
specimens showed PTCH1 expression in 81–100% of the tumor cells, only intensity for PTCH1 was
determined and categorized into negative or low (intensity 0–1, immunoscore 0) and high (intensity
2–3, immunoscore 1).
4.3. Cell Lines and Cell Culture
Two esophageal cancer cell lines were used, OE21 derived from ESCC of the upper esophagus
and OE33 derived from a poorly differentiated Barrett’s associated tumor of the distal esophagus. Both
cell lines were donated by Dr. F.A. Kruyt, Department of Medical Oncology, University Medical Center
Groningen and were independently DNA verified as EC cell lines by the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) in 2012. These cell lines
are commonly used in esophageal cancer research. OE21 and OE33 were cultured in GIBCO RPMI
1640 medium (Life Technologies) supplemented with 10% FCS and 1% of penicillin/streptomycin in an
incubator of 5% CO2 and 37 ◦C. Both cell lines were passaged in 1:5 at 70% confluency.
4.4. Fluorescence Activated Cell Sorting (FACS)
CD44+/CD24− cells and CD44+/CD24+ cells were sorted with both OE21 and OE33 using
antibodies directed against CD44 (BD Biosciences, 550989, San Jose, CA, USA) and CD24 (BD
Biosciences, 555427) with MoFlo Asterios cell sorter (Beckman Coulter, Woerden, The Netherlands).
Isotype controls were used to compensate for aspecific binding of the antibodies. CD24 antibody
conjugated with FITC and CD44 antibody conjugated with PE along with their corresponding isotype
controls (BD Biosciences, 555748, 555749, respectively) were used. The most left and right (3–15%)
population of CD44+/CD24−, respectively, CD44+/CD24+ populations were sorted.
4.5. Sphere Culture and Sphere Count
100,000 cells of each sorted population, CD44+/CD24− and CD44+/CD24+, were seeded in
triplicate in each well of a six-well plate with 2 mL of mammocult serum-free medium with supplement
(Stemcell Technologies, Vancouver, Canada). Mammocult serum-free medium was used instead
of Neural Basal A medium supplemented with N2, bFGF and FGF-2 as previously described by
Smit et al. [16]. because of its more potent sphere forming ability in both cell lines without distortion of
the results. The wells were coated with agarose to prevent the attachment of cells onto the bottom of
the plate. The concentration agarose was 0.023 g/mL dissolved in distilled water. A total volume of
0.2 mL of mammocult was added each day to nourish the cells. To ensure balance of the total amount
of formed spheres in both cell lines, 2 × 104 sorted OE33 cells and 1 × 105 OE21 cells were seeded for
the modulation of the HH pathway experiments. Pictures of spheres were taken under the microscope
after five days. For the quantification, only sphere-like structure in a homogenized aliquot of 100 µL
were counted.
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4.6. HH Pathway Modulation
OE21 and OE33 cells were sorted for CD44+/CD24− and CD44+/CD24+ populations and seeded
in each well of a six-well plate coated with agarose to prevent the attachment of the cells onto the
bottom of the plate. For OE21 1 × 105 cells were used for each population while 2 × 104 cells were used
for OE33 to achieve similar amount of spheres in both cell lines. Each sorted population of both cell
lines were cultured in Mammocult medium supplemented by 0.4 µg/mL human recombinant protein
Sonic Hedgehog (R and D systems) reconstituted in PBS + 0.1% BSA, according to manufacturer
datasheet, to generate spheres. This treated population was compared to its control, which consisted
of only Mammocult and PBS + 0.1% BSA. The relative amount of spheres compared to control was
calculated after five days. Five nanomoles of vismodegib reconstituted in DMSO was used according
to manufacturer instructions (IC50 of 3 nM) and was also based on the biological effect in both cell
lines according to viability assays (data not shown). vismodegib also blocks ABC transporter, ABCG2,
however only when applied in relatively higher concentrations (IC50 of 1.4 µM) according to the
manufacturer datasheet. FACS analyses on LSRII (BD Biosciences) were performed on the expression
of CD44+/CD24− and CD44+/CD24+ in OE21 and OE33 after 48 h 5 nM vismodegib treatment in RPMI
media and their controls, which consisted of RPMI supplemented with DMSO. Flow cytometry data
were analyzed using Kaluza (Beckman Coulter, Woerden, The Netherlands). This software offers flow
cytometry analysis software solution designed for high content data. The same cells of both cells lines
used in the FACS experiment were seeded in Mammocult medium to generate spheres. This was done
immediately after collecting the cells for the FACS analyses to ensure reliability and consistency. For
OE21 1 × 105 cells were seeded and for OE33 2 × 104 cells were seeded. Spheres were counted after
five days.
4.7. RNA Extraction, First Strand Analysis and qPCR
Total RNA was extracted from the sorted cell populations using RNAeasy micro extraction kit
(Qiagen, Venlo, The Netherlands). RNA concentration was measured by Nanodrop (Isogen Life Sciences,
De Meern, The Netherlands. To ensure RNA quality, standards according to the manufacturer’s
datasheet were followed. Subsequently, the first cDNA strand was produced using 500 ng/µL RNA
and SuperScript® VILO™ cDNA synthesis kit (Life Technologies, Bleiswijk, The Netherlands). A qPCR
array (Qiagen) of 84 genes related to cancer stemness was performed on the CD44+/CD24− and
CD44+/CD24+ sorted cells of OE21 and OE33. Additionally, solid tumors generated from the same cell
lines obtained from xenografts, as reported previously [16], were used as controls as these populations
represent a differentiated group of cells. The xenografts were generated by isolating either sorted
CD44+/CD24−, CD44+/CD24+ or unsorted cells OE21 and OE33 cells before injecting either of these
populations into animals. These cells were not treated with CRT. These arrays were performed on
Biorad CFX connect 96 wells plate according the protocol of the manufacturer. Genes that were >2-fold
up-regulated in the CD44+/CD24− CSC population compared to controls were considered relevant.
The gene that appeared to be up-regulated in both cell lines was validated by separate qPCR analyses.
YWHAZ was used as an endogenous control for normalization. qPCR was performed using SYBR
green (Biorad, Lunteren, The Netherlands) to measure the expression of the genes.
4.8. Clonogenic Assay
To assess the sensitivity of vismodegib treated cells, a clonogenic assay was performed. Cells were
seeded in a 12-well plate at 1 × 105 cells per well and incubated with/without vismodegib (5 nM). After
48 hours, cells were photon irradiated using a 137Cs source (IBL 637 Cesium-137 γ-ray machine). After
irradiation cells were washed and harvested from the plate following incubation with trypsin-EDTA.
The cells were then counted and seeded in 60 mm cell culture dishes at concentrations ranging from
200–1000 cells depending on the radiation dose or carboplatin concentration. To assess the response to
carboplatin following vismodegib treatment, cells were seeded in triplicate at 500 cells per 60 mm cell
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culture plate at all carboplatin concentrations. For the irradiation experiments, cells were seeded in
triplicate at multiple concentrations of 200, 500 and 1000 cells per plate per irradiation dose. The cells
were incubated at 37 ◦C and 5% CO2 for 10–12 days, after which they were stained with clonogenic
assay stain solution (50% methanol, 10% acetic acid, 1% w/v Coomassie brilliant blue). Colonies (≥50
cells) were counted and the surviving fraction was calculated.
4.9. Statistical Analysis
All experiments were at least performed three times except for the qPCR array experiment
screening for CSC related genes which was performed in duplicate for each sample and each cell
line. However, the gene of interest was validated separately by qPCR of at least three experiments.
Shown data are presented as mean and shown error bars represent standard deviation unless otherwise
stated. Groups were compared with Student’s t-test. IHC results of PTCH1 were compared with the
Fishers exact test and of SHH were compared with the chi-square test for trend using SPSS (version 22).
A p-value <0.05 was considered significant.
5. Conclusions
In this study, the potential of targeting the Hedgehog pathway to enhance the efficacy of esophageal
cancer was investigated. Enhanced levels of Sonic Hedgehog and its receptor Patched1 were observed
in microresidual disease biopsies compared to biopsies from control patients. In vitro modulation of
the HH pathway efficiently altered CSC populations, while inhibition of the pathway can be used to
enhance sensitivity to common esophageal cancer treatments. The HH pathway therefore offers a
potentially attractive target to enhance esophageal cancer treatment.
Supplementary Materials: The supplementary materials are available online at http://www.mdpi.com/2072-6694/
11/6/821/s1. Table S1: Fold change of expression in important cancer stemness-related genes. Figure S1: Gating
strategies of the FACS experiments. (A) The left 3–15% proportion of CD44+/CD24- cells and the right 3–15%
proportion of CD44+/CD24+ cells were sorted for the induction of the HH pathway by SHH. (B) CD44 and CD24
expression in OE21 and OE33 cells of vismodegib (5nM) sample compared to control sample. Gates of all samples
were set individually after correcting for aspecific binding by running isotype controls. Figure S2: Viability curves
of OE21 and OE33 after treatment Vismodegib Relative number of viable cells after different concentrations of
vismodegib treatment compared to no vismodegib treatment (control). Viable cells were counted with trypan blue.
5 nM was subsequently chosen as the concentration to use.
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